- Vecihi Batuman, MD, FASN (2018)
- Anthony Chang, MD, FASN (2017)
- Eric P. Cohen, MD (2017)
- Mona D. Doshi, MD (2018)
- Amaka Edeani, MBBS (2017)
- Kevin W. Finkel, MD, FASN (2018)
- Ilya Glezerman, MD (2018)
- Leal C. Herlitz, MD (2018)
- Edgar A. Jaimes, MD (2018)
- Kenar D. Jhaveri, MD, FASN (2018)
- Albert Q. Lam, MD (2018)
- Divya Monga, MD (2017)
- Shveta S. Motwani, MD, MS (2018)
- Robert H. Weiss, MD (2018)
- Motoko Yanagita, MD, PhD (2018)
- Mark D. Okusa, MD, FASN (2016)
Why onconephrology? While all nephrologists address nephrology problems in cancer patients, many of these problems are increasingly complex. To provide the best nephrology care for cancer patient, we must understand rapidly changing protocols and therapies.
Emerging kidney toxicities associated with drugs targeting VEGF and TKIs and other signaling pathways, tumor lysis syndrome, cytotoxic chemotherapy-induced kidney toxicities, kidney problems in myeloma, tumor or treatment-related microangiopathies and glomerulonephritis, stem cell transplant-associated acute and chronic kidney injuries, obstructive uropathies, severe fluid and electrolytes abnormalities, and dosing and timing of chemotherapy in CKD and ESRD patients: these and other complex problems, and their increasing frequency and severity, provide a unique and unprecedented opportunity for nephrologists to improve treatment for cancer patients worldwide.
Onconephrologists help cancer care teams prevent kidney problems or resolve them as they arise, and improve patient outcomes. Research in cancer nephrology is already improving kidney care in cancer patients. A more focused approach to cancer nephrology may also help address challenges like renal cell carcinoma in end-stage renal disease.
The American Society of Nephrology believes onconephrology represents an emerging frontier in the fight against kidney disease.